Last updated: July 31, 2026
Darifenacin hydrobromide is a mature oral antimuscarinic used for overactive bladder, including urgency urinary incontinence, urgency and urinary frequency. The U.S. reference product, Enablex extended-release tablets, lost meaningful regulatory exclusivity years ago. Current commercial risk is generic substitution, therapeutic competition from mirabegron, vibegron, oxybutynin, solifenacin and trospium, and declining branded value rather than new patent litigation.
No late-stage clinical development program is driving darifenacin hydrobromide. The current opportunity is concentrated in low-cost generic supply, regional commercialization, formulation efficiency and potential combination or lifecycle studies.
What is darifenacin hydrobromide approved to treat?
Darifenacin hydrobromide is a selective muscarinic M3 receptor antagonist. It is administered as an extended-release oral tablet at 7.5 mg or 15 mg once daily.
The FDA approved Enablex on December 22, 2004, for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency (U.S. Food and Drug Administration [FDA], 2004). The drug was initially developed by Pfizer and commercialized through Novartis.
| Attribute |
Darifenacin hydrobromide |
| Drug class |
Selective M3 muscarinic antagonist |
| Therapeutic area |
Overactive bladder |
| Reference brand |
Enablex |
| Dosage form |
Extended-release tablet |
| U.S. strengths |
7.5 mg and 15 mg |
| Route |
Oral |
| Initial U.S. approval |
December 22, 2004 |
| Regulatory pathway |
New drug application |
| Current competition |
Generic darifenacin and alternative OAB drugs |
| Biosimilar exposure |
None; darifenacin is a small molecule |
Darifenacin has greater M3 receptor selectivity than nonselective antimuscarinics. Its commercial positioning has relied on bladder efficacy and a potentially differentiated cognitive and cardiac tolerability profile, although anticholinergic adverse effects remain relevant, particularly dry mouth, constipation and urinary retention.
What is the latest clinical-trial status of darifenacin?
Darifenacin has no visible late-stage trial program comparable with an investigational or recently launched medicine. The clinical evidence base is mature and consists primarily of completed studies supporting approval, postmarketing evaluation and comparative research in overactive bladder.
Clinical studies have evaluated:
- Darifenacin versus placebo in urgency urinary incontinence and overactive bladder.
- Once-daily 7.5 mg and 15 mg extended-release dosing.
- Dose escalation from 7.5 mg to 15 mg.
- Comparisons with oxybutynin and other antimuscarinics.
- Patient-reported outcomes, continence episodes and urinary frequency.
- Tolerability in older adults and patients with comorbidities.
The clinical-trial profile is therefore maintenance-oriented rather than innovation-oriented. Searches of public trial records should distinguish completed darifenacin studies from trials involving other M3 antagonists or unrelated combination products (ClinicalTrials.gov, 2024).
What clinical advantages does darifenacin have?
Darifenacin’s potential commercial advantages are tied to receptor selectivity and once-daily extended release. Its limitations include:
| Potential advantage |
Commercial limitation |
| M3-selective pharmacology |
Still associated with anticholinergic adverse events |
| Once-daily dosing |
Competes with once-daily branded and generic alternatives |
| Established efficacy data |
Clinical evidence is no longer a strong source of differentiation |
| Oral extended-release formulation |
Formulation technology is mature and reproducible |
| Generic availability |
Low pricing limits product-level revenue |
The most important clinical liability is the class-wide anticholinergic burden. The FDA label warns about urinary retention, gastrointestinal obstruction, controlled-angle glaucoma, reduced gastrointestinal motility and central nervous system effects. Strong CYP3A4 inhibitors can increase darifenacin exposure, and dosing adjustments may be required (FDA, 2004).
When does darifenacin lose exclusivity?
Darifenacin has already lost U.S. market exclusivity. The original product’s exclusivity period expired long before current generic competition. The product is not protected by an active small-molecule regulatory exclusivity period that would prevent ANDA competition.
The relevant commercial timeline is:
| Date or period |
Event |
| 2004 |
FDA approved Enablex |
| 2009-2010 |
Early U.S. generic-entry activity emerged after primary protection weakened |
| 2010s |
Generic darifenacin became available in the United States |
| Current period |
Mature generic market with limited branded protection |
Patent expiration dates vary by patent family, jurisdiction, terminal disclaimers and patent-term adjustment. The core commercial protection associated with darifenacin did not create a durable barrier into the 2020s. Patent-term calculations should be confirmed against the relevant Orange Book editions and USPTO records before being used for litigation or transaction decisions.
What patents protect darifenacin hydrobromide?
The historical patent estate covered the active chemical entity, pharmaceutical compositions and extended-release delivery technology. Public records associated with darifenacin include patents covering substituted quinuclidine derivatives and formulations used in overactive bladder treatment.
The principal patent categories were:
- Chemical compound patents covering darifenacin and related quinuclidine derivatives.
- Salt and pharmaceutical composition patents.
- Extended-release tablet formulations.
- Therapeutic-use claims for urinary disorders.
- Manufacturing and formulation process claims.
The most important patent risk has shifted from blocking patents to residual formulation and process claims. A generic applicant can avoid a formulation patent through a different excipient system, release profile or manufacturing process if the alternative does not infringe the asserted claims.
How strong is the darifenacin patent estate?
The current estate is commercially weak for U.S. market exclusion because:
- The product has been genericized.
- The principal patent term has expired or is no longer commercially blocking.
- The dosage form is an established oral extended-release tablet.
- Generic manufacturers can rely on abbreviated approval pathways.
- Any remaining formulation claims are narrower than the original product claims.
Patent strength may be higher in individual countries where patent prosecution, local launch timing or enforcement history differs. A global freedom-to-operate review must separate expired composition patents from surviving formulation or process patents.
What is the Orange Book status of darifenacin?
Enablex was listed in the FDA Orange Book as an approved extended-release product. Generic darifenacin products are approved through ANDA pathways and are therapeutically equivalent where listed by FDA as substitutable.
The Orange Book is the relevant U.S. source for:
- Reference-listed drug status.
- Listed patents.
- Patent expiration information.
- Therapeutic-equivalence codes.
- Approved generic strengths and dosage forms.
A current transaction or launch decision should use the latest Orange Book edition rather than relying on historical patent tables. Older listings can remain in secondary databases after their commercial significance has ended, particularly where patents have expired or been delisted.
Which companies compete with darifenacin hydrobromide?
Competition comes from both generic darifenacin suppliers and alternative OAB therapies.
Generic darifenacin manufacturers
U.S. generic supply has historically included companies such as Teva, Actavis or related entities, Mylan or Viatris, Lupin and other ANDA holders. Manufacturer participation changes as products are discontinued, transferred or placed on intermittent supply.
The economic structure favors suppliers with:
- FDA-approved 7.5 mg and 15 mg strengths.
- Stable API sourcing.
- Reliable extended-release manufacturing.
- Low-cost packaging and distribution.
- Contract access to pharmacies, wholesalers and Medicaid plans.
Competing drugs
| Drug |
Class |
Commercial position |
| Darifenacin |
M3-selective antimuscarinic |
Mature generic |
| Solifenacin |
Antimuscarinic |
Broad generic use and established demand |
| Oxybutynin |
Antimuscarinic |
Low-cost, high historical awareness |
| Trospium |
Antimuscarinic |
Generic alternative with distinct pharmacokinetics |
| Tolterodine |
Antimuscarinic |
Mature generic |
| Mirabegron |
Beta-3 adrenergic agonist |
Branded and generic competition; non-anticholinergic mechanism |
| Vibegron |
Beta-3 adrenergic agonist |
Newer branded competitor |
Mirabegron and vibegron are the principal mechanistic alternatives because they do not rely on muscarinic blockade. Their uptake can reduce demand for antimuscarinics among patients and prescribers concerned about dry mouth, constipation, cognitive effects or overall anticholinergic burden.
What generic entry risks exist for darifenacin?
Generic entry risk is already realized rather than prospective. The key risks are price erosion, customer concentration and supply instability.
A generic launch scenario typically produces:
- Rapid substitution in pharmacy channels.
- Reduced average selling price.
- Greater contracting pressure from wholesalers and payers.
- Periodic product exits by low-margin manufacturers.
- Market share concentration among the lowest-cost reliable suppliers.
For a new entrant, regulatory approval alone may not create an attractive return. The market can support incremental suppliers only when there is a supply shortage, manufacturing-cost advantage, differentiated packaging or access to a regional market with limited competition.
Paragraph IV litigation is unlikely to be the central issue for a mature darifenacin launch because generic products already exist and primary patent barriers have expired. Any new Paragraph IV case would more likely involve a later-listed formulation or process patent rather than the original composition of matter.
Does darifenacin face biosimilar risk?
No. Darifenacin hydrobromide is a chemically synthesized small molecule, not a biologic. It is subject to generic ANDA competition, not the biosimilar pathway under the Public Health Service Act.
The relevant competitive questions are bioequivalence, formulation release characteristics, manufacturing quality and therapeutic equivalence. Biosimilar interchangeability, reference-product biologic exclusivity and biologic patent dance issues do not apply.
What is the darifenacin market outlook through 2030?
Public company disclosures generally do not report darifenacin revenue as a separate material product line. Market-research estimates also vary because some reports combine all antimuscarinic overactive-bladder products, while others include retail sales, hospital sales or only branded revenue.
A defensible projection is therefore an indexed scenario rather than a falsely precise dollar forecast.
| Scenario |
2024-2030 assumption |
2030 market index, 2024 = 100 |
| Downside |
Continued anticholinergic displacement and price erosion |
45-60 |
| Base case |
Stable generic use with gradual class migration |
60-75 |
| Upside |
Supply disruptions, regional growth or limited competitor exits |
75-90 |
The base case implies a low-growth or declining market. Volume may remain stable in older patients and in cost-sensitive formularies, but revenue should contract as average prices fall and beta-3 agonists gain use.
What drives the darifenacin forecast?
The main demand drivers are:
- Prevalence of overactive bladder.
- Aging populations.
- Generic affordability.
- Physician familiarity.
- Insurance formulary placement.
- Anticholinergic prescribing restrictions.
- Uptake of mirabegron and vibegron.
- Availability of reliable generic supply.
The strongest downside factor is not patent expiry. It is therapeutic substitution. Even after genericization, darifenacin can retain volume where payers prioritize low acquisition cost. Its share is more vulnerable when prescribers prioritize non-anticholinergic treatment or cognitive-risk reduction.
What licensing deals affect darifenacin?
Darifenacin’s main commercial history involved development and commercialization arrangements associated with Pfizer, Novartis and later product-rights changes. It is not a current licensing hotspot comparable with newly launched specialty medicines.
The relevant transaction issues are:
- Whether a party owns the local marketing authorization.
- Whether the product is supplied through a third-party manufacturer.
- Whether trademark rights are separate from drug approval rights.
- Whether API and finished-dose supply agreements remain active.
- Whether local regulatory filings can be transferred.
A buyer should value darifenacin primarily as a regulated generic or mature branded product, not as an innovation asset. The transaction case depends on supply reliability, geographic pricing and channel access.
What manufacturing and IP barriers remain?
Manufacturing is the more material barrier. Extended-release tablets require reproducible dissolution performance, control of content uniformity and validated scale-up. A manufacturer must also manage:
- API impurity profiles.
- Hydrobromide salt consistency.
- Release-rate control.
- Stability under regional climate conditions.
- Bioequivalence of the finished product.
- Changes to excipients or manufacturing sites.
The manufacturing barrier is moderate, not high. Several manufacturers have demonstrated that the product can be reproduced through standard oral solid-dose technology. The strongest competitive advantage is likely to come from cost, quality systems and supply continuity rather than proprietary formulation science.
Key Takeaways
- Darifenacin hydrobromide is an established M3-selective antimuscarinic for overactive bladder.
- Enablex received FDA approval in 2004 and no longer has meaningful U.S. regulatory exclusivity.
- The product is subject to generic, not biosimilar, competition.
- No late-stage clinical program is driving current value.
- Formulation and manufacturing patents are less commercially important than they were during the branded period.
- Generic supply, pricing and therapeutic substitution determine market performance.
- Mirabegron and vibegron create the strongest non-anticholinergic competitive pressure.
- A reasonable 2030 base case is a 25% to 40% decline from a 2024 indexed market level, with upside only from supply shortages or regional opportunities.
- Revenue exposure is difficult to isolate because public companies generally do not disclose darifenacin sales separately.
- A commercial diligence review should prioritize current Orange Book listings, ANDA ownership, supplier continuity and country-specific patent status.
FAQs
Is darifenacin hydrobromide still commercially available?
Yes. Generic darifenacin extended-release tablets remain the primary commercial form in markets where approved and supplied.
Is darifenacin stronger than oxybutynin?
Clinical response varies by patient. Darifenacin has M3 selectivity, while oxybutynin is less selective and is often associated with a broader anticholinergic adverse-effect profile.
Can a generic manufacturer file a Paragraph IV certification for darifenacin?
A manufacturer can use a Paragraph IV certification against a qualifying listed patent, but the practical significance is limited where the principal patents have expired and generic darifenacin products are already marketed.
Is darifenacin associated with cognitive impairment?
As an antimuscarinic, darifenacin carries class-related anticholinergic concerns. Its M3 selectivity may differentiate it pharmacologically, but it does not eliminate the need to assess cognitive and other anticholinergic risks.
What is the main investment risk in darifenacin?
The main risk is sustained revenue and price erosion from mature generic competition and migration to beta-3 adrenergic agonists, rather than a new clinical or biosimilar threat.
References
-
ClinicalTrials.gov. (2024). Search results for darifenacin. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (2004). Enablex (darifenacin hydrobromide) extended-release tablets prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Patent and Trademark Office. (2024). Patent Center and patent term adjustment information. https://patentcenter.uspto.gov/
-
National Library of Medicine. (2024). DailyMed: Darifenacin hydrobromide extended-release tablets. https://dailymed.nlm.nih.gov/
